Recent advances in drug therapy for chronic kidney disease
10.3760/cma.j.cn441217-20240820-00819
- VernacularTitle:慢性肾脏病的药物治疗新进展
- Author:
Xin FAN
1
;
Luyao LI
1
;
Lin FANG
1
;
Sha WANG
1
;
Xiangdong YANG
1
Author Information
1. 山东大学齐鲁医院肾内科，济南 250012
- Publication Type:Journal Article
- Keywords:
Renal insufficiency, chronic;
Sodium-glucose transporter 2 inhibitors;
Mineralocorticoid receptor antagonists;
Glucagon-like peptide-1 receptor agonists
- From:
Chinese Journal of Nephrology
2025;41(2):138-143
- CountryChina
- Language:Chinese
-
Abstract:
Chronic kidney disease (CKD) is a significant global public health issue. In recent years, several new drugs have shown substantial efficacy in CKD treatment. Sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists improve renal outcomes in CKD patients through various mechanisms, and also demonstrate favorable effects on cardiovascular outcomes. Novel agents, including endothelin receptor antagonists, are accumulating clinical evidence for delaying kidney disease progression, with ongoing development of new therapeutic targets. This article reviewed the latest research progress of these drugs in CKD treatment, offering new perspectives and reference points for comprehensive CKD management.
